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Structured Abstract  
Aims  
Progression of atrial fibrillation (AF) from paroxysmal to persistent forms is an active field of 
research. The influence of AF progression on health related quality of life (HRQoL) is currently 
unknown. We aimed to assess the influence of AF progression on HRQoL, and whether this 
association is mediated through symptoms, treatment and major adverse events.  
Methods 
In the Euro Heart Survey, 967 patients were included with paroxysmal AF who filled out EuroQoL-5D 
at baseline and at 1 year follow-up.  
Results 
Those who progressed (n=132, 13.6%) developed more problems during follow-up than those who 
did not, on all EuroQoL-5D domains (increase in problems on Mobility 20.5% vs 11.4%; Self-care 
12.9% vs 6.2%; Usual activities 23.5% vs 14.0%; Pain / discomfort 20.5% vs 13.7%; and Anxiety / 
depression 22.7% vs 15.7%; all p<0.05), leading to a decrease in utility (baseline 0.744±0.26, follow-
up 0.674±0.36; difference -0.07 (95%CI [-0.126,-0.013], p=0.02). Multivariate analysis showed that 
the effect of progression on utility is mediated by a large effect of adverse events (stroke (-0.27 
(95%CI [-0.43,-0.11]); p=0.001), heart failure (-0.12 (95%CI [-0.20,-0.05]); p=0.001), malignancy (-0.31 
(95%CI [-0.56,-0.05]); p=0.02) or implantation of an implantable cardiac defibrillator (-0.12 (95%CI [-
0.23,-0.02]); p=0.03)), as well as symptomatic AF (-0.04 (95%CI [-0.08,-0.01]); p=0.008).  
Conclusion 
AF progression is associated with a decrease in HRQoL. However, multivariate analysis revealed that 
AF progression itself does not have a negative effect on HRQoL, but that this effect can be attributed 
to a minor effect of the associated symptoms and a major effect of associated adverse events. 
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Condensed abstract 
In 967 patients with paroxysmal atrial fibrillation (AF), progression to persistent AF (n=132) was 
associated with a decrease in quality of life during 1 year (difference in utility -0.07 (95%CI [-0.013,-
0.126],p=0.02)). This was mediated by a major effect of adverse events, and a minor effect of AF 
being symptomatic. 
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What’s new 
• AF progression is associated with a decrease in quality of life 
• This decrease can be attributed to the associated occurrence of symptoms and adverse 
events, not to progression itself 
Introduction 
Atrial fibrillation (AF), the most common cardiac arrhythmia, has been demonstrated to lead to a 
considerable reduction in health-related quality of life (HRQoL).1 While rarely life-threatening in 
itself, AF is associated with several arrhythmia-associated symptoms, such as palpitations, exercise 
intolerance, dizziness and dyspnoea, which can have substantial influence on the possibility to 
undertake daily activities.2 In addition, AF is associated with an increased incidence of major adverse 
events, such as stroke and heart failure, which are associated with increased mortality, but also have 
detrimental effects on daily functioning and HRQoL.3 The consequences of AF treatment, such as side 
effects of drugs, interventions, and especially hospitalization, may also have a negative impact on 
HRQoL. Lastly, the diagnosis of AF may be associated with considerable psychological distress.  
AF is a progressive disease that clinically may progress from short-lasting self-terminating paroxysms 
towards more non-self-terminating sustained forms, such as persistent and permanent AF.4 This 
progression is usually accompanied by electrical and structural changes of the left atrium.5 Recent 
reports suggest that predictors of AF progression lie in factors that represent an impaired vascular 
status, leading to the observation that patients who progress from paroxysmal to more sustained 
forms of AF are those who will have adverse events.6 As AF progression appears to correlate with 
adverse events, one may hypothesize that AF progression has a detrimental effect on HRQoL.  
Current treatment of AF has HRQoL as a major focus, and aims to preserve or improve HRQoL by two 
strategies4: on one hand, to prevent serious adverse events through life style changes, 
anticoagulation upon indication and adequate vascular protective therapy, and on the other hand to 
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alleviate symptoms associated with AF if necessary. In addition to this, prevention of AF progression 
has recently been proposed as a treatment goal in itself.7 The influence of AF progression on HRQoL, 
and whether this is mediated by adverse events and symptoms, is however currently unknown. 
In this report, we used the data from the Euro Heart Survey (EHS) on Atrial Fibrillation to assess the 
influence of AF progression on HRQoL, and whether this association is mediated through symptoms 
or concomitant vascular disease and major cardiac events.  
Methods 
A description of the methods and data collection of the EHS on AF has been given in detail earlier.8 In 
2003 and 2004, 5,333 consecutive patients with AF on an ECG or Holter recording in the previous 12 
months were included in the Euro Heart Survey, a large-scale registry, at cardiology departments of 
182 hospitals in 35 countries. The study protocol was submitted to the institutional review board or 
ethical committee of all participating centres and approved or waived for the requirement of formal 
approval being an observational survey.  
Only patients with paroxysmal AF at baseline were included: patients with known paroxysmal AF 
(spontaneous conversion to sinus rhythm <7 days; 1,517 patients) and patients with first detected AF 
that converted to sinus rhythm spontaneously or through pharmacological cardioversion during the 
index visit (238 patients). Out of  these, rhythm status at follow-up was available in 1,219 patients, 
and amongst these, complete EuroQoL-5D data at both baseline and follow-up was available for 967 
patients. The definition of AF-progression by de Vos et al6 was used: paroxysmal AF at baseline 
becoming persistent or permanent AF at 1-year follow-up, or first detected AF at baseline with 
spontaneous or pharmacological cardioversion to sinus rhythm during admission becoming 
persistent or permanent AF at 1-year follow-up.  
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Quality of life measurements 
The EuroQol-5D consists of five domains (mobility, self-care, usual activities, pain / discomfort, and 
anxiety / depression) with three possible answers for each domain (no problems, moderate 
problems, or severe problems), generating 35=243 possible health states. These health states, at 
baseline and follow-up, were translated into a single index – the utility score– using the United 
Kingdom time trade-off value set.9 No problems on each of the EuroQol-5D domains corresponds to 
a utility of 1.0 (best possible health), with deductions for reporting problems on any of the EuroQol-
5D. A utility score of 0 is equivalent to death, while  negative values are  possible (indicating a health 
status worse than death). 
Statistical analysis 
Data analysis was performed with IBM SPSS for Windows statistical software (version 23.0, IBM 
Corp., Armonk, NY, USA) and regression analysis using Stata Statistical Software Release 10.0 
(StataCorp LP, College Station, TX, USA). Baseline characteristics for the groups with and without AF 
progression are presented as mean±SD for continuous variables, or number (percentage) for 
categorical variables. Baseline characteristics of the groups were compared using an independent t-
test for continuous variables and a χ2–test for categorical variables. Increase in problems experienced 
at each of the EuroQoL-5D domains was defined as ‘no problems’ at baseline and ‘some problems’ or 
‘severe problems’ at 1-year follow-up, or ‘some problems’ at baseline and ‘severe problems’ at 
follow-up. The fractions showing an increase were compared for the group with and without AF 
progression using χ2–tests. Utility scores at baseline and follow-up were compared using paired-
samples t-testing.  
Regression analyses 
Apart from AF progression, the following parameters were tested for a significant relation with the 
change in utility over 1 year (p<0.1) in univariate ordinary least squares regression using robust 
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standard errors: age at inclusion, sex, domestic status, body mass index, level of physical activity, 
medical history (hypertension, diabetes, coronary artery disease, myocardial infarction, valvular 
heart disease, congestive heart failure, hyperthyroidism or hypothyroidism, chronic obstructive 
pulmonary disease, malignancy, peripheral vascular disease, renal failure, transient ischemic attack 
(TIA), stroke), AF symptoms (palpitations, chest pain, dyspnoea, syncope, dizziness, fatigue), events 
during follow-up (stable angina, acute coronary syndrome, TIA, ischemic or haemorrhagic stroke, 
peripheral embolism, pulmonary embolism, syncope, asystole, malignancy, heart failure), AF related 
parameters (AF recurrence, number of pharmacological cardioversions, number of electrical 
cardioversions,  use of beta-blockers, calcium channel blocker, anti-arrhythmic drugs (Vaughan-
Williams class 1a, 1c, 3)) and cardiac treatment during follow-up (catheter ablation, AF surgery, 
pacemaker or ICD implantation, percutaneous coronary intervention, coronary artery bypass surgery, 
valvular surgery). 
All parameters that showed a significant relation were included in multivariate linear regression 
using robust standard errors. No significant correlations between predictors were found. Backward 
variable elimination (p>0.05) was applied, not forcing any specific variable to be retained. 
All tests were performed 2-sided. Overall, a p value of <0.05 was considered statistically significant. 
Results 
The baseline characteristics of the patients with complete EuroQoL-5D at baseline and follow-up 
(n=967) were comparable to those with incomplete EuroQoL-5D (n=252), with only differences in 
regular physical activity (36.8% vs 27.6%; p=0.008) and history of stroke (2.4% vs 6.5%; p = 0.001).  
In the 967 patients included, progression of AF occurred in 132 patients (13.7%). Baseline 
characteristics of patients with and without AF progression are shown in Table 1. Patients with AF 
progression were on average older (66.1±11.2 vs. 62.8±13.1 years; p=0.007) and had larger left atria 
(LA diameter 45.9±8.8 vs 42.9±7.6 mm; p < 0.001). Hypertension (71.2% vs 59.8%), left ventricular 
hypertrophy (50.4% vs 29.8%) coronary artery disease (36.0% vs 23.2%), heart failure (31.5% vs 
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15.5%), chronic obstructive pulmonary disease (18.3% vs 9.6%) and history of TIA (10.7% vs 5.2%; all 
p<0.01) were more prevalent in the AF progression group, leading to a higher mean CHA2DS2VASc-
score of 3.2±1.9 vs 2.4±1.7 (p<0.01) and HATCH-score of 2.2±1.5 vs 1.3±1.3 (p<0.01). Medication use, 
further medical history and event rates in both groups were reported previously. 6 
At baseline, patients that will progress experienced more problems (some problems or severe 
problems) on each domain of the EuroQoL-5D than those who did not progress (Table 2). 
Furthermore, in the patients that progressed, the percentage of patients that experienced more 
problems on each of the domains at 1-year follow-up than at baseline was significantly higher than in 
the patients that did not progress (Figure 1; Mobility 20.5% vs 11.4%; Self-care 12.9% vs 6.2%; Usual 
activities 23.5% vs 14.0%; Pain / discomfort 20.5% vs 13.7%; and Anxiety / depression 22.7% vs 
15.7%; all p<0.05). 
While the calculated utility for the group without AF progression increases during 1 year (baseline 
0.796±0.23, 1 year 0.814±0.23; p= 0.04; difference +0.018 (95% CI [0.008,0.033])), the utility 
decreased significantly in the group with AF progression (baseline 0.744±0.26, follow-up 0.674±0.36; 
p=0.02; difference -0.07 (95% CI [-0.126,-0.013])) (Figure 2).  
Multivariate analysis showed that stroke (-0.27 (95% CI [-0.43,-0.11]); p=0.001), heart failure (-0.12 
(95% CI [-0.20,-0.05]); p=0.001), malignancy (-0.31 (95% CI [-0.56,-0.05]); p=0.017) or implantation of 
an implantable cardiac defibrillator (-0.12 (95% CI [-0.23,-0.02]); p=0.03) during follow-up had the 
largest negative effect on the change in utility during this year. Patients with symptomatic AF had a 
reduction in utility of -0.04 (95% CI [-0.08,-0.01]; p=0.008), except when this symptom was dizziness 
(+0.06 (95% CI [0.02,0.10]); p=0.004). Patients with diabetes mellitus experienced an increase of 
utility during follow-up of 0.04 (95% CI [0.01,0.07]; p=0.006) (Table 3). Notably, in multivariate 
regression analysis, progression of AF is not a determinant of change in utility. 
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Discussion 
This report is the first to show the association between AF progression and HRQoL. From this report, 
it can be concluded that AF progression is associated with a decrease in quality of life (HRQoL) during 
the year in which progression occurs, indicated by an increase in problems reported on each of the 
EuroQoL-5D domains, leading to a change in utility of -0.07 (95% CI [-0.126,-0.013]) which appears 
clinically significant.10 Upon correcting for major adverse events and symptoms during follow-up, this 
association disappears. This suggests that the decrease of HRQoL associated with AF progression is 
mediated by adverse events and symptoms: there is a significant relationship between AF 
progression and adverse events and symptoms,6 a significant relation between utility and both 
adverse events and symptoms and progression, and the relationship between progression and utility 
becomes non-significant upon correction for adverse events and symptoms.  
The main determinants of a reduction in utility in this population of patients with paroxysmal AF 
were the occurrence of stroke, heart failure, malignancy and ICD implantation during follow-up, 
which was already known for AF patients in general3. Already, one of the cornerstones of current 
treatment is focusing on the reduction of the incidence of cardiac adverse events,4 but the fact that 
these events still occur indicates that our current treatment strategies are not sufficient yet. 
Although the percentage of patients that will experience such an event is low, the effect on HRQoL is 
large. This report emphasizes that strategies focused on the prevention of adverse events may 
ultimately have a major influence on HRQoL, irrespective of their influence on AF progression.  
Next to adverse events, symptomatic AF is a determinant of the change in utility during one year. The 
utility of patients that remain symptomatic is reduced modestly (-0.04 (95% CI [-0.08,-0.01]; 
p=0.008)). This effect is cancelled out if the symptom is dizziness, as this symptom is usually readily 
treatable by reducing the dose of negative chronotropic drugs or implanting a pacemaker in case of 
sinus arrest. If patients remain symptomatic, despite the efforts of patient and physician, it is only to 
be expected that this has a detrimental effect on the quality of life. 3 Furthermore, this underlines 
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the need to continue focusing on reducing AF symptoms through more modern rhythm control 
strategies, with pharmacological as well as interventional measures.  
Patients in this cohort who suffered from diabetes experienced an increase in quality of life during 
one year. This may be explained by the correction for events in the multivariate analysis, as diabetes 
without complications may have little influence on the perceived HRQoL. The increase in HRQoL may 
be explained by the fact that these patients visit a doctor more frequently than patients without 
diabetes, which may have a beneficial effect, or they get more comfortable living with their diabetes 
as time passes since their diagnosis.  
On one hand, one may hypothesize that AF progression in itself is a cause for adverse events. Based 
on this hypothesis, preventing AF progression may be instrumental in  preventing the associated 
events and the associated decrease in HRQoL. Although trials have never shown benefit of rhythm 
over rate control in the long term on clinical endpoints,11, 12 more recent reports have shown signals 
that there is an association between the duration of AF episodes and stroke risk,13, 14 and that rhythm 
control may reduce the number of strokes15 and mortality.16 Furthermore, our current strategy of 
rhythm control has not been shown to improve HRQoL to a clinically significant extent.17, 18 This led to 
the design of the EAST trial, that aims to inhibit AF progression through modern and early rhythm 
control, in which HRQoL will be a key secondary outcome.7 Results from this trial should show 
whether early rhythm control could limit progression – and thereby retain HRQoL more effectively 
than a rate control strategy. Our current study suggests that preventing AF progression may only 
influence HRQoL if indeed this focus on inhibition of rhythm deterioration prevents major adverse 
cardiac and cerebrovascular events. As rhythm control generally encompasses intensive treatment, 
including potentially hazardous anti-arrhythmic drug use and invasive therapy, the net effect of 
inhibition of progression of AF on the quality of life remains to be determined.  
On the other hand, based on the association between the occurrence of major adverse events and 
AF progression, it may be hypothesized that both AF progression and adverse events are the result of 
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an underlying common mechanism. One of the proposed underlying mechanisms is an early state of 
hypercoagulability leading to both an atrial substrate for more persistent forms of AF and adverse 
events.19 Early intervention in this hypercoagulable state may thus improve both progression rates 
and incidence of adverse events. Furthermore, this hypothesis implicate a less stringent need for 
rhythm control, as events do not relate to the rhythm status, such that  side effects of intensive 
treatment associated with aggressive rhythm control can be averted.20   
Lastly, the results reported here support the notion that – also from the perspective of HRQoL – the 
current daily practice of classifying AF by the duration of the episodes - ie paroxysmal and persistent 
AF - rather than the underlying pathology may need reconsideration,21 as the results indicate that 
HRQoL is not so much determined by the duration of the episodes of the arrhythmia, but more by 
the associated events and symptoms.   
Strengths and Limitations 
The major strength of this report lies in the fact that the Euro Heart Survey provided longitudinal 
data on a large group of real life patients across Europe, which represent the daily clinical population 
better than results acquired in clinical trials.  
For this report, only those patients who filled out the HRQoL questionnaires both at baseline and 
follow-up were used, which may have led to excluding those patients that were too sick or frail to fill 
out the questionnaires, or who died during follow-up. This may have influenced HRQoL measures, 
especially since from a previous report on the study population from which this cohort is selected, it 
is known that responders differed from non-responders on both demographic and disease-related 
characteristics.3 Furthermore, HRQoL was measured using EuroQoL-5D as disease specific HRQoL 
questionnaires were not yet available. We corrected for treatments chosen, but were not able to 
assess the effectiveness of these treatments. The data from this study were acquired in 2003-2004, 
yet the outcomes we describe have remained relevant over the past decade, as AF progression is still 
a clinically identifiable problem, as well as the importance of stroke, heart failure, malignancy, ICD 
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implantation and symptomatic AF with respect to HRQoL remain relevant.  We were not able to 
determine whether AF progression preceded events. Lastly, assessment of personality was not 
included in the EHS, which did not allow us to correct the user reported quality of life for differences 
in personality and thus coping strategies to deal with adverse events.  
Conclusion 
To conclude, quality of life in patients with AF progression decreases, which is largely caused by 
adverse events and to a smaller extent by AF symptoms. An effect of inhibition of AF progression on 
HRQoL is thus mainly to be expected if future studies show that inhibiting AF progression leads to 
fewer adverse events.  
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Table 1. Baseline characteristics, grouped by the presence of AF progression.  
 All patients No AF progression AF Progression  
n= 967 835 132 p-value 
Age (years) 63.3 ± 12.9 62.8 ± 13.1 66.1 ± 11.2 0.007 
Female 417 (43.1) 353 (42.3) 64 (48.5) 0.18 
Body Mass Index (km/m2) 27.4 ± 4.2 27.4 ± 4.1 27.9 ± 4.9 0.18 
Regular physical activity 356 (36.8) 320 (40.7) 36 (30.0) 0.13 
Echocardiogram  
Left atrial diameter (mm) 43.3 ± 7.8 42.9 ± 7.6 45.9 ± 8.8 < 0.001  
Left ventricular hypertrophy 262 (32.7) 205 (29.8) 57 (50.4) < 0.001 
Type of AF 
First detected 149 (15.3) 127 (15.1) 22 (16.7) 0.64 
Paroxysmal 825 (84.7) 715 (84.9) 110 (83.3) 
Underlying disease 
Hypertension 593 (61.3) 499 (59.8) 94 (71.2) 0.01 
Coronary artery disease 205 (25.0) 164 (23.2) 41 (36.0) 0.003 
Diabetes mellitus 127 (13.1) 102 (12.2) 25 (18.9) 0.06 
Valvular disease 180 (18.8) 149 (18.0) 31 (24.2) 0.09 
Heart failure 169 (17.7) 128 (15.5) 41 (31.5) < 0.001 
Chronic obstructive pulmonary disease 103 (10.8) 79 (9.6) 24 (18.3) 0.003 
Hyperthyroidism 50 (5.4) 42 (5.3) 8 (6.2) 0.67 
History of stroke  23 (2.4) 17 (2.1) 6 (4.6) 0.08 
History of TIA 57 (5.9) 43 (5.2) 14 (10.7) 0.01 
Malignancy 41 (4.4) 38 (4.7) 3 (2.4) 0.24 
Peripheral vascular disease 57 (6.0) 46 (5.6) 11 (8.5) 0.19 
Renal failure 41 (4.2) 33 (4.0) 8 (6.1) 0.26 
CHA2DS2-VASc score 2.5 ± 1.8 2.4 ± 1.7 3.2 ± 1.9 < 0.001 
HATCH score 1.5 ± 1.4 1.3 ± 1.3 2.2 ± 1.5 < 0.001 
Data are expressed as the mean±SD or number (percentage) of patients. AF = atrial fibrillation; TIA = 
transient ischemic attack; CHA2DS2-VASc-score = Congestive heart failure (1 point), Hypertension (1 
point), Age >75 years (2 points), Diabetes mellitus (1 point), Prior Stroke or TIA (2 points), Vascular 
disease (1 point), Age 65 - 74 years (1 point), Sex category (female = 1 point); HATCH-score = 
Hypertension (1 point), Age >75 years (1 point), Stroke or transient ischemic attack (2 points), 
Chronic obstructive pulmonary disease (1 point), and Heart failure (2 points). 
  
18 
 
Table 2. Percentage of patients that report no, some and severe problems on the five domains of 
EuroQoL-5D at baseline and after 1 year, in those that will not progress (n=835) versus those that will 
(n=132). P-values are derived from the comparison between non-progressors and progressors, a p-
value <0.05 is considered significant.  
 Baseline  Follow-up  
 Non-progressors Progressors p Non-progressors Progressors p 
Problems: No  Some Severe No Some Severe No  Some Severe No Some Severe 
Mobility 67.2 32.1 0.7 57.6 40.9 1.5 0.09 68.9 30.5 0.6 51.5 42.4 6.1 <0.001 
Self-care 89.3 10.3 0.4 80.3 19.7 0.0 0.006 88.5 11.3 0.2 78.8 15.9 5.3 <0.001 
Usual activities 72.9 25.9 1.2 56.8 42.4 0.8 <0.001 70.4 28.0 1.6 50.0 41.7 8.3 <0.001 
Pain / discomfort 61.7 35.9 2.4 53.8 43.9 2.3 0.21 65.7 32.3 1.9 53.8 40.2 6.1 0.002 
Anxiety / 
depression 
62.9 32.5 4.7 50.0 43.9 6.1 0.02 64.1 32.5 3.5 47.7 43.2 9.1 <0.001 
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Table 3. Determinants of the change in utility during one year of follow-up. Notably, progression of 
atrial fibrillation (AF) is not a determinant of change in utility.  
 Coefficient p 
Diabetes mellitus  0.04 [0.01,0.07] 0.006 
Symptomatic AF  -0.04 [-0.08,-0.01] 0.008 
Dizziness 0.06 [0.02,0.10] 0.004 
Stroke during FU -0.27 [-0.43,-0.11] 0.001 
Heart failure during FU -0.12 [-0.20,-0.05] 0.001 
Malignancy during FU -0.31 [-0.56,-0.05] 0.017 
ICD during FU -0.12 [-0.23,-0.02] 0.030 
Shown are the coefficient [95% CI] and p-value of multivariate ordinary least squares regression. 
CI=Confidence Interval; FU=Follow-up; ICD=Implantable Cardiac Defibrillator. 
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Figure 1. Percentage of patients reporting an increase, no change and a decrease problems on the 
EuroQoL-5D domain at 1 year than at baseline, for the groups without and with AF-progression. * 
indicates p < 0.05. 
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Figure 2. In patients without progression of atrial fibrillation (AF), the utility increases from 
0.796±0.23 at baseline to 0.814±0.23 at 1 year (p=0.04), while in patients with AF progression it 
decreases from 0.744±0.26 to 0.674±0.36 (p=0.02). Utility scores range from 0 (health state 
equivalent to death) to 1.0 (best possible health), negative values are possible. * indicates p < 0.05. 
